Table 2
Component: 503O13 | Molecular weight: 1205.975 | Reported molar entry: Not recovered | Calculated mass: Not calculated
sales@dcchemicals.com
503O13
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 2
Component: Cholesterol | Molecular weight: 386.65 | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 2
Component: DSPC | Molecular weight: 790.15 | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 2
Component: DMG-PEG2000 | Molecular weight: 2507 | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 3
Parameter: Organic phase | Reported procedure / limitation: Lipidoid, cholesterol, DSPC and mPEG2000-DMG were dissolved in 90% ethanol plus 10% 10 mM sodium citrate by volume. | Source: Methods: Formulation of LNPs, p.8
Table 3
Parameter: Aqueous phase and loading | Reported procedure / limitation: siRNA was diluted in 10 mM sodium citrate. Lipidoid:siRNA was 5:1–10:1 by mass depending on the experiment. This is not a total-lipid:siRNA mass ratio; no N/P value is specified. | Source: Methods: Formulation of LNPs, p.8
Table 3
Parameter: Mixing | Reported procedure / limitation: Equal volumes of lipid and siRNA solutions were rapidly mixed by microfluidic device or pipetting. The paper does not assign a specific mixing implementation to each 503O13 experiment. | Source: Methods: Formulation of LNPs, p.8
Table 3
Parameter: Buffer exchange | Reported procedure / limitation: Dilution in PBS followed by dialysis against PBS for 90 min using a 3,500-MWCO cassette. | Source: Methods: Formulation of LNPs, p.8
Table 3
Parameter: Optimization boundary | Reported procedure / limitation: The general series used 50:38.5:(11.5−X):X lipidoid/cholesterol/DSPC/PEG-lipid. The specific X for optimized 503O13 is not supplied. The separately optimized 304O13 PEG fraction cannot be transferred to 503O13. | Source: Methods p.8; Results p.4 and Fig.6d
Table 3
Parameter: Unreported process details | Reported procedure / limitation: Buffer pH, precise microfluidic flow settings, final concentration and an experiment-specific 503O13 loading ratio are not reported in the recovered method. A sterile-filtration step is not stated there. | Source: Methods p.8
Table 4
Measurement / batch: Particle diameter / PDI / encapsulation | Reported result: No numerical 503O13-specific values recovered. Table 1 describes other individual lipidoids; library ranges are not product-specific specifications. | Evidence context: Main article Table 1 and Fig.6
Table 4
Measurement / batch: Apparent particle pKa | Reported result: The 500-series text places 503O13 among candidates satisfying pKa ≥5.5; no exact 503O13 value is tabulated. | Evidence context: Results p.6 and Fig.6
Table 4
Measurement / batch: Tolerability endpoint | Reported result: 503O13 appears in the 5 mg/kg siRNA body-weight panel; this is a limited body-weight endpoint, not a full toxicology assessment. | Evidence context: Supplementary Fig.9, PDF p.13
Table 5
Experiment and dose: Initial hepatic Factor VII screen Female C57BL/6 mice ≥6 weeks; anti-FVII siRNA; intravenous tail vein; 5 mg/kg siRNA; injection volume 0.01 mL/g | Readout and comparator: Readout: 48 h Comparator: PBS / FVII baseline | Result and source: 503O13 is among the 500-series formulations producing >95% FVII silencing. The exceptions identified by the authors were 509O13 and 510O13. n=3; mean±SD. Fig.6b; Results pp.6–8; In vivo gene silencing, p.9
Table 5
Experiment and dose: Unoptimized dose-response ranking 503O13 screening formulation; female C57BL/6 mice; intravenous anti-FVII siRNA | Readout and comparator: Readout: 48 h Comparator: Other second-generation lipidoids at the screening composition | Result and source: Nonoptimized 503O13 EC50 is approximately 0.05 mg/kg by the plotted bar; this is an approximate graphical value. It is separate from the optimized 0.01 mg/kg result. Fig.6c, p.7
Table 5
Experiment and dose: Optimized Factor VII dose response Optimized 503O13 LNP; intravenous anti-FVII siRNA; doses plotted 5, 0.5, 0.1, 0.03, 0.01 and 0.003 mg/kg | Readout and comparator: Readout: 48 h Comparator: 503O13 with nontargeting siRNA | Result and source: Reported EC50 0.01 mg/kg siRNA. The nontargeting control did not suppress FVII. n=3; mean±SD; one-way ANOVA F(6,14)=86.69, P<0.0001; Tukey comparison P<0.05 for each tested active-siRNA dose versus siControl. Fig.6d and caption, p.7; Results p.8
Table 5
Experiment and dose: Body-weight screen 500-series LNPs including 503O13; 5 mg/kg siRNA | Readout and comparator: Readout: Time point not specified in the figure caption Comparator: PBS | Result and source: No statistically significant body-weight decrease versus PBS by Student’s t-test. The 503O13 group has three plotted animals; no 503O13-specific cytokine, clinical-chemistry or histology conclusion follows from this panel. Supplementary Fig.9, PDF p.13